Amid a renewed interest in alternatives to psychotherapy and medication to treat depression, there is limited data as to how different stakeholders perceive of the risks and benefits of psychiatric electroceutical interventions (PEIs), including electroconvulsive therapy (ECT) and deep brain stimulation (DBS). To address this gap, we conducted 48 semi-structured interviews, including 16 psychiatrists, 16 persons diagnosed with depression, and 16 members of the general public. To provide a basis of comparison, we asked participants to also compare each modality to front-line therapies for depression and to neurosurgical procedures used for non-psychiatric conditions. Across all stakeholder groups, perceived memory loss was the most frequently mentioned potential risk with ECT. The most discussed benefits across all stakeholder groups were efficacy and quick response. Psychiatrists most often referenced effectiveness when discussing ECT, while patients and the public did so when discussing DBS. Taken as a whole, these data highlight stakeholders’ contrasting perspectives on the risks and benefits of electroceuticals.

随着人们对心理疗法和药物治疗抑郁症的替代品重新产生兴趣，关于不同利益相关者如何看待包括电休克疗法 (ECT) 和深部脑刺激 (DBS) 在内的精神病电疗法 (PEI) 的风险和益处的数据有限. 为了弥补这一差距，我们进行了 48 次半结构化访谈，其中包括 16 名精神科医生、16 名被诊断患有抑郁症的人和 16 名公众。为了提供比较的基础，我们要求参与者将每种方式与抑郁症的一线疗法和用于非精神疾病的神经外科手术进行比较。在所有利益相关者群体中，感知记忆丧失是最常提到的 ECT 潜在风险。所有利益相关者群体中讨论最多的好处是效率和快速响应。精神科医生在讨论 ECT 时最常提及有效性，而患者和公众在讨论 DBS 时也这样做。总体而言，这些数据突出了利益相关者对电子产品风险和收益的不同观点。